Page 177 - Genentech News Today

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease...

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

MRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

– In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28% – – Up to 80%... | April 16, 2023

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this type

The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.The benefit with the combination persisted regardless of patients’ tumor mutational burden status, findings of the randomized phase 2B KEYNOTE-942 trial showed.

/PRNewswire/ -- The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when...

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this type of... | June 19, 2023

These companies from various corners of the globe are well positioned for the future.